Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
245.44
+6.57 (2.75%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for ALNY stock have an average target of 298.59, with a low estimate of 170 and a high estimate of 400. The average target predicts an increase of 21.65% from the current stock price of 245.44.
Analyst Consensus: Buy
* Price targets were last updated on Nov 18, 2024.
Analyst Ratings
The average analyst rating for ALNY stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 10 | 10 | 10 | 10 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 8 | 7 | 7 | 6 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 23 | 23 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $296 | Buy | Reiterates | $296 | +20.60% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $400 | Strong Buy | Reiterates | $400 | +62.97% | Nov 18, 2024 |
| Wolfe Research | Wolfe Research | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $400 | Strong Buy | Reiterates | $400 | +62.97% | Nov 4, 2024 |
| Raymond James | Raymond James | Buy Maintains $275 → $298 | Buy | Maintains | $275 → $298 | +21.41% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
2.29B
from 1.83B
Increased by 25.14%
Revenue Next Year
2.69B
from 2.29B
Increased by 17.35%
EPS This Year
-2.08
from -3.52
EPS Next Year
-1.22
from -2.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.5B | 3.4B | 4.8B | |||
| Avg | 2.3B | 2.7B | 3.6B | |||
| Low | 2.1B | 2.2B | 2.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 34.3% | 47.7% | 78.4% | |||
| Avg | 25.1% | 17.4% | 34.9% | |||
| Low | 16.8% | -3.5% | 5.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.84 | 2.83 | 6.47 | |||
| Avg | -2.08 | -1.22 | 2.62 | |||
| Low | -2.88 | -3.63 | -0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.